The potential use of viral genomic markers in estimating the neurovirulence of oral poliomyelitis vaccine (OPV): regulatory aspects.
Fenyves
A
A
Paul-Ehrlich-Institut, Langen, Germany.
D000818:Animals; D005819:Genetic Markers; D000882:Haplorhini; D006801:Humans; D011051:Poliomyelitis / Q000209:etiology / Q000517:prevention & control; D017955:Poliovirus / Q000235:genetics / Q000472:pathogenicity*; D011055:Poliovirus Vaccine, Oral / Q000009:adverse effects / Q000592:standards* / Q000633:toxicity; D011237:Predictive Value of Tests; D012449:Safety; D014774:Virulence / Q000235:genetics
D005819:Genetic Markers; D011055:Poliovirus Vaccine, Oral